Veracyte to Present Practice-Changing Oncology Data at ASCO 2026 Highlighting Advances in Breast and Prostate Cancer Genomic Testing
Veracyte announced that major new clinical data involving its Prosigna Breast and Decipher Prostate genomic tests will be presented during the 2026 Annual Meeting of the American Society of Clinical Oncology, taking place May 29 through June 2 in Chicago, Illinois. The company said the findings from two landmark phase III clinical trials are expected to provide significant evidence supporting the use of genomic diagnostics to guide treatment decisions in breast and prostate cancer.
The presentations, which include results from the OPTIMA and ENZAMET studies, are expected to demonstrate how genomic classifiers can help physicians tailor therapies more precisely to individual patients, potentially reducing overtreatment while improving outcomes for those most likely to benefit from intensified therapy.
Veracyte’s participation at ASCO 2026 reflects the growing role of precision medicine in oncology and the increasing integration of genomic testing into standard cancer care pathways. The company’s genomic assays are designed to provide biologic insights into tumor behavior, helping clinicians determine the most appropriate treatment strategy based on the molecular characteristics of a patient’s disease.
OPTIMA Trial Highlights Potential of Prosigna in Early Breast Cancer
One of the most anticipated presentations will feature results from the OPTIMA phase III clinical trial, a large prospective randomized study evaluating the role of genomic testing in guiding chemotherapy decisions for patients with early-stage breast cancer.
The trial was led by researchers at University College London and supported by the National Institute for Health Research. Investigators enrolled more than 4,400 patients with estrogen receptor-positive (ER-positive), HER2-negative early breast cancer who were considered to have clinically high-risk disease.
The primary goal of the OPTIMA study was to address a longstanding challenge in breast cancer treatment: determining which patients truly benefit from adjuvant chemotherapy and which patients may be able to avoid chemotherapy and its associated toxicities without compromising outcomes.
Chemotherapy remains an important treatment option for many breast cancer patients, but it is also associated with significant short- and long-term side effects, including fatigue, neuropathy, cardiovascular complications, fertility concerns, and secondary malignancies. As a result, oncologists have increasingly sought tools capable of identifying patients who may safely avoid unnecessary treatment.
The OPTIMA trial evaluated whether the Prosigna Breast test could provide clinically actionable genomic information to support these treatment decisions. Prosigna is designed to analyze tumor biology and classify recurrence risk, offering physicians additional data beyond traditional clinical and pathological factors.
Results from the study will be presented by Dr. Robert Stein of University College London, who serves as chief investigator for the OPTIMA trial. The presentation is scheduled for Saturday, May 30, during the Breast Cancer—Local/Regional/Adjuvant session at ASCO.
According to Veracyte, the findings are expected to provide Level 1A evidence supporting the use of Prosigna-guided treatment decisions in patients with high-risk breast cancer. In clinical research, Level 1A evidence represents one of the highest standards of evidence quality, typically derived from well-designed randomized controlled trials.
Kelly Marcom, M.D., medical director for breast cancer at Veracyte, described the trial as a major milestone for precision oncology in breast cancer. She emphasized that the results may significantly influence how clinicians approach treatment planning for a large patient population.
The company believes the findings could help expand confidence in genomic-guided treatment strategies, enabling physicians to better personalize therapy based on individual tumor biology rather than relying solely on traditional clinicopathologic features.
ENZAMET Trial Evaluates Decipher Prostate in Advanced Disease
Veracyte will also present important findings from the ENZAMET trial, an international prospective randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
The study focused on patients with metastatic hormone-sensitive prostate cancer and evaluated the ability of the Decipher Prostate genomic classifier to predict which patients may benefit from treatment intensification using docetaxel chemotherapy in combination with androgen deprivation therapy and enzalutamide.
Results from the analysis will be presented by Dr. Christopher Sweeney of the South Australian Immunogenomics Cancer Institute during the Genitourinary Cancer session on May 30.
The OPTIMA Decipher Prostate test is designed to assess genomic risk and help stratify patients according to the biological aggressiveness of their tumors. The ENZAMET analysis specifically evaluated whether patients with higher genomic classifier scores derived greater benefit from the addition of docetaxel to standard hormonal therapy regimens.
According to Veracyte, the findings provide Level 1B evidence supporting the role of Decipher in identifying patients most likely to benefit from triplet therapy approaches.
The study highlights the broader trend toward precision treatment intensification in prostate cancer. While aggressive treatment strategies may improve outcomes for some patients, they can also increase the risk of significant side effects, including fatigue, neuropathy, immunosuppression, and impacts on quality of life. Genomic testing may therefore help physicians balance therapeutic benefit against potential toxicity more effectively.
Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer, said the combined evidence from the OPTIMA and ENZAMET studies demonstrates the growing value of genomic diagnostics across multiple cancer types.
He noted that the studies reinforce the concept of matching treatment intensity to an individual patient’s risk profile, allowing clinicians to provide more targeted care while avoiding unnecessary treatment-related side effects whenever possible.
Additional Prostate Cancer Research Expands Genomic Applications
In addition to the ENZAMET findings, Veracyte and its collaborators will present several other studies involving genomic risk stratification and prostate cancer management.
One oral presentation will examine clinico-transcriptomic risk stratification approaches to guide treatment intensification with abiraterone in patients with high-risk prostate cancer. The combined analysis incorporates data from multiple major clinical trials, including NRG/RTOG 9202, 9413, 9902, and 0521.
The presentation will be delivered by Dr. Krishnan R. Patel of the National Cancer Institute and will explore how transcriptomic information may improve treatment selection and therapeutic optimization.
Another presentation by Dr. Daniel Keizman of Tel Aviv Sourasky Medical Center will focus on genomic classifier-driven risk reclassification in early prostate cancer. The study investigates how genomic data can identify distinct transcriptomic signatures that may influence prognosis and treatment strategies.
These presentations collectively underscore growing interest in integrating genomic classifiers into prostate cancer management across both localized and advanced disease settings.
Real-World Studies and Biomarker Research at ASCO
Beyond the headline oral presentations, Veracyte and its collaborators will also showcase several poster presentations covering real-world outcomes analyses, biomarker studies, and molecular characterization research.
One study will evaluate treatment patterns and outcomes among octogenarians with high-risk localized prostate cancer using national real-world data. The analysis explores how genomic risk assessment may influence treatment decisions in older patient populations.
Additional presentations focus on bladder cancer research, including biomarker analyses from the SURE-01 trial evaluating neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.
Researchers will also present studies examining the relationship between artificial intelligence-driven multimodal analysis and genomic classifier results in localized prostate cancer, highlighting the increasing convergence of genomics and computational oncology tools.
Another molecular profiling study will evaluate residual disease following neoadjuvant treatment with sacituzumab govitecan, pembrolizumab, or combination therapy in muscle-invasive bladder cancer patients.
Together, OPTIMA the broad range of presentations reflects Veracyte’s strategy of expanding the clinical utility of genomic testing beyond traditional prognostic applications into treatment selection, therapeutic intensification, and longitudinal disease management.
Precision Oncology Continues to Reshape Cancer Care
The data being presented by Veracyte at ASCO 2026 arrive at a time when precision oncology continues to gain momentum across the cancer treatment landscape.
Genomic testing technologies are increasingly being integrated into clinical guidelines and treatment workflows as physicians seek more individualized approaches to therapy selection. By identifying the molecular features that drive cancer behavior, genomic classifiers can help clinicians better determine which patients require aggressive treatment and which patients may safely avoid unnecessary interventions.
For breast cancer patients, genomic assays such as Prosigna may reduce exposure to chemotherapy in patients unlikely to benefit while ensuring OPTIMA appropriate treatment for those at higher risk of recurrence. In prostate cancer, genomic tools like Decipher may help guide increasingly complex decisions regarding treatment intensification strategies.
As evidence supporting genomic-guided care continues to expand, studies such as OPTIMA and ENZAMET may play an important role in shaping future oncology practice standards and advancing more personalized cancer treatment approaches worldwide.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC.
